Octavio Espinoza Ligand Pharmaceuticals Inc (LGND) insider trading activity

Octavio Espinoza is Chief Financial Officer of LIGAND PHARMACEUTICALS INC. Currently has a direct ownership of 18,879 shares of LGND, which is worth approximately $2.03 Million. The most recent transaction as insider was on Mar 04, 2025, when has been sold 5,000 shares (Common Stock) at a price of $115.03 per share, resulting in proceeds of $575,150. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 18.9K

8.56% 3M change

36.55% 12M change

Total Value Held $2.03 Million

Octavio Espinoza Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Mar 04 2025	SELL Open market or private sale	$575,150 $115.03 p/Share	5,000 Reduced 20.94%	18,879 Common Stock
Mar 04 2025	BUY Grant, award, or other acquisition	-	7,484 Added 22.11%	26,363 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$363,240 $120.0 p/Share	3,027 Reduced 11.25%	23,879 Common Stock
Feb 14 2025	SELL Payment of exercise price or tax liability	$787,200 $120.0 p/Share	6,560 Reduced 19.6%	26,906 Common Stock
Feb 14 2025	BUY Grant, award, or other acquisition	-	12,819 Added 29.45%	30,709 Common Stock
Dec 23 2024	SELL Open market or private sale	$244,842 $116.37 p/Share	2,104 Reduced 9.25%	20,647 Common Stock
Dec 05 2024	SELL Payment of exercise price or tax liability	$229,605 $123.51 p/Share	1,859 Reduced 7.55%	22,751 Common Stock
Sep 20 2024	SELL Open market or private sale	$132,510 $103.93 p/Share	1,275 Reduced 4.93%	24,610 Common Stock
Sep 17 2024	BUY Exercise of conversion of derivative security	$102,489 $68.97 p/Share	1,486 Added 5.43%	25,885 Common Stock
Aug 28 2024	BUY Exercise of conversion of derivative security	$47,913 $63.63 p/Share	753 Added 2.99%	24,399 Common Stock
Jun 28 2024	BUY Other acquisition or disposition	$16,209 $60.71 p/Share	267 Added 1.12%	23,646 Common Stock
May 17 2024	SELL Open market or private sale	$446,818 $86.66 p/Share	5,156 Reduced 18.07%	23,379 Common Stock
May 17 2024	BUY Exercise of conversion of derivative security	$419,239 $60.61 p/Share	6,917 Added 19.51%	28,535 Common Stock
May 16 2024	SELL Open market or private sale	$194,704 $86.0 p/Share	2,264 Reduced 9.48%	21,618 Common Stock
May 15 2024	SELL Open market or private sale	$505,136 $86.01 p/Share	5,873 Reduced 19.74%	23,882 Common Stock
Feb 28 2024	SELL Open market or private sale	$12,384 $88.46 p/Share	140 Reduced 0.47%	29,755 Common Stock
Feb 28 2024	BUY Exercise of conversion of derivative security	$72,237 $57.15 p/Share	1,264 Added 4.06%	29,895 Common Stock
Feb 27 2024	BUY Grant, award, or other acquisition	-	7,208 Added 20.11%	28,631 Common Stock
Feb 15 2024	SELL Payment of exercise price or tax liability	$110,407 $74.65 p/Share	1,479 Reduced 6.46%	21,423 Common Stock
Dec 05 2023	SELL Payment of exercise price or tax liability	$75,645 $59.61 p/Share	1,269 Reduced 5.25%	22,902 Common Stock
Oct 01 2023	SELL Payment of exercise price or tax liability	$20,732 $59.92 p/Share	346 Reduced 1.41%	24,171 Common Stock
Jun 30 2023	BUY Other acquisition or disposition	$21,292 $56.78 p/Share	375 Added 1.51%	24,517 Common Stock
Feb 23 2023	BUY Grant, award, or other acquisition	-	6,046 Added 20.03%	24,142 Common Stock
Feb 15 2023	SELL Payment of exercise price or tax liability	$61,960 $72.98 p/Share	849 Reduced 4.48%	18,096 Common Stock
Dec 30 2022	BUY Other acquisition or disposition	$15,614 $56.78 p/Share	275 Added 1.43%	18,945 Common Stock

Octavio Espinoza

Chief Financial Officer

San Diego, CA

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells LGND shares.

Notify only if

Value

Insider Trading

Get notified when an Ligand Pharmaceuticals Inc insider buys or sells LGND shares.

Notify only if

Operation

Value

Type

News

Receive news related to LIGAND PHARMACEUTICALS INC

Track Activities on LGND

Account